Evaluation of triage strategies and screening intervals in a human papillomavirus based cervical cancer screening program in women living with human immunodeficiency virus in Botswana

博茨瓦纳人类免疫缺陷病毒感染妇女基于人乳头瘤病毒的宫颈癌筛查计划的分诊策略和筛查间隔的评估

基本信息

  • 批准号:
    10655623
  • 负责人:
  • 金额:
    $ 25.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-07-01 至 2027-05-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT Primary high-risk human papillomavirus (HPV) testing has become first line screening for cervical cancer in high-income countries. The feasibility of this approach in low- and middle-income countries is less clear, as is the role of primary HPV screening among women living with human immunodeficiency virus (HIV). Evaluating the performance of cervical cancer screening algorithms using primary HPV testing in high HIV prevalence settings like Botswana is essential for establishing an evidence-based strategy for cervical cancer screening in populations with a high burden of HIV living in low- and middle-income countries. The proposed study evaluates innovative HPV-based cervical cancer screening algorithms in women living with HIV (WLHIV) and builds a longitudinal cohort to evaluate long-term outcomes. With internal departmental funding, I have begun recruitment of a cohort of 3,000 women, 50% of whom are living with HIV, in South East District, Botswana. Participants in this cohort undergo baseline cervical cancer screening with high-risk HPV testing and 3 types of visual triage evaluation: 1) visual assessment with acetic acid, 2) colposcopy, and 3) automated visual evaluation. Biopsy with histopathology is collected as the gold standard in comparing the efficacy of these HPV-based screening algorithms. Excisional treatment is offered as indicated by colposcopy and biopsy results. Aim 1 of the proposed K08 will evaluate the performance of these HPV-based screening algorithms, as well as HPV testing alone in detecting cervical dysplasia in WLHIV. Additionally, in Aim 2, I will conduct interval HPV-based cervical cancer screening for the WLHIV in this cohort to evaluate safe and effective screening intervals. Specifically, I will repeat HPV testing at 2 years in WLHIV who tested positive for HPV and had benign pathology at baseline, and at 3 years in WLHIV who tested negative for HPV at baseline. Women will undergo triage testing according to the findings of the baseline screening study. Based on the data from baseline and interval screening, in Aim 3, I will develop a pilot implementation study to evaluate the incorporation of HPV-based cervical cancer screening into routine health services, in collaboration with the Ministry of Health and Wellness of Botswana. This K08 will provide protected research time and build skills in advanced clinical data analytics, clinical trial design, and implementation science to become an independent NIH-funded researcher. My career goal is to improve the health and wellness of women through evaluation and implementation of high-performance cervical cancer screening that is within reach of all women regardless of their geography and socioeconomic status. The research will be conducted with the support of the Beth Israel Deaconess Medical Center and through the Botswana Harvard AIDS Institute Partnership with which the PI has a long-standing research appointment. Furthermore, this research will be done in collaboration with the Ministry of Health and Wellness of Botswana, thus impacting national cervical cancer screening policy as well as international policy for WLHIV.
摘要 高危型人乳头瘤病毒(HPV)检测已成为宫颈癌的一线筛查, 高收入国家。这种方法在低收入和中等收入国家的可行性不太清楚, 初级HPV筛查在感染人类免疫缺陷病毒(HIV)的女性中的作用。评价 在艾滋病毒高流行率地区使用初级HPV检测的宫颈癌筛查算法的性能 在博茨瓦纳这样的环境中,建立一个以证据为基础的宫颈癌筛查战略至关重要, 艾滋病毒高负担人群生活在低收入和中等收入国家。拟定研究 评估艾滋病毒感染妇女(WLHIV)中基于HPV的宫颈癌筛查创新算法, 建立一个纵向队列来评估长期结果。有了内部资金,我开始 在博茨瓦纳东南区招募了一批3 000名妇女,其中50%是艾滋病毒感染者。 该队列中的参与者接受基线宫颈癌筛查,高危HPV检测和3种类型的 视觉分诊评估:1)醋酸视觉评估,2)阴道镜检查,3)自动视觉 评价收集活检和组织病理学检查作为金标准,比较这些治疗的疗效。 基于HPV的筛查算法。根据阴道镜检查和活组织检查的指示,提供切除治疗 结果拟议K08的目标1将评估这些基于HPV的筛查算法的性能, 以及单独HPV检测在检测WLHIV患者宫颈发育不良中的作用。此外,在目标2中,我将进行间隔 在该队列中进行基于HPV的宫颈癌筛查,以评估筛查的安全性和有效性 的间隔具体来说,我将在2年后对HPV检测呈阳性且 基线时为良性病变,基线时HPV检测阴性的WLHIV患者3年时为良性病变。妇女将 根据基线筛选研究的结果进行分诊测试。根据来自 在目标3中,我将开展一项试点实施研究,以评估 与联合国艾滋病规划署合作,将基于HPV的宫颈癌筛查纳入常规保健服务, 博茨瓦纳卫生和福利部。这K08将提供受保护的研究时间,并建立技能, 先进的临床数据分析,临床试验设计和实施科学,成为一个独立的 NIH资助的研究员。我的职业目标是通过评估和评估, 实施所有妇女都能得到的高效宫颈癌筛查, 地理位置和社会经济地位。这项研究将在以色列贝丝的支持下进行。 女执事医疗中心,并通过博茨瓦纳哈佛艾滋病研究所伙伴关系, 有一个长期的研究预约此外,这项研究将与 博茨瓦纳卫生和健康部,从而也影响到国家宫颈癌筛查政策 作为世界艾滋病病毒的国际政策。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Feasibility and acceptability of an HPV self-testing strategy: lessons from a research context to assess for ability to implement into primary care at a national level in Botswana.
  • DOI:
    10.3389/fgwh.2023.1300788
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Luckett, Rebecca;Ramogola-Masire, Doreen;Harris, Devon A.;Gompers, Annika;Gaborone, Kelebogile;Mochoba, Lorato;Ntshese, Lapelo;Mathoma, Anikie;Kula, Maduke;Shapiro, Roger;Larson, Elysia
  • 通讯作者:
    Larson, Elysia
COVID-19 as a catalyst for reimagining cervical cancer prevention.
  • DOI:
    10.7554/elife.86266
  • 发表时间:
    2023-04-18
  • 期刊:
  • 影响因子:
    7.7
  • 作者:
    Luckett R;Feldman S;Woo YL;Moscicki AB;Giuliano AR;de Sanjosé S;Kaufmann AM;Leung SOA;Garcia F;Chan K;Bhatla N;Stanley M;Brotherton J;Palefsky J;Garland S;International Papillomavirus Society (IPVS) Policy Committee
  • 通讯作者:
    International Papillomavirus Society (IPVS) Policy Committee
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rebecca Luckett其他文献

Rebecca Luckett的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rebecca Luckett', 18)}}的其他基金

Evaluation of triage strategies and screening intervals in a human papillomavirus based cervical cancer screening program in women living with human immunodeficiency virus in Botswana
博茨瓦纳人类免疫缺陷病毒感染妇女基于人乳头瘤病毒的宫颈癌筛查计划的分诊策略和筛查间隔的评估
  • 批准号:
    10483598
  • 财政年份:
    2022
  • 资助金额:
    $ 25.59万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 25.59万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 25.59万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 25.59万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 25.59万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 25.59万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 25.59万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 25.59万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 25.59万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 25.59万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 25.59万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了